Filtered By:
Drug: Metformin

This page shows you your search results in order of date.

Order by Relevance | Date

Total 446 results found since Jan 2013.

Real ‐world risk of cardiovascular diseases in patients with type 2 diabetes associated with sodium–glucose cotransporter 2 inhibitors in comparison with metformin: A propensity score‐matched model analysis in Japan
Risk of CVD using SGLT2Is compared with metformin. AbstractWe aimed to compare the effects of cardiovascular disease risk in Japanese patients with type  2 diabetes on sodium–glucose cotransporter 2 inhibitors (SGLT2Is) or metformin. This retrospective, real-world cohort study was carried out using a claims database and propensity score matching; 58,402 eligible patients (29,201 per group) were included. The outcomes included nonfatal myocardi al infarction, angina pectoris, nonfatal stroke, hospitalization for heart failure and composite end-points. The hazard ratio (HR) for the composite end-point was 0.79, which w...
Source: Journal of Diabetes Investigation - July 31, 2023 Category: Endocrinology Authors: Takeshi Horii, Yoichi Oikawa, Akira Shimada, Kiyoshi Mihara Tags: SHORT REPORT Source Type: research

Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes
CONCLUSION: The addition of GLP1RA was associated with primary reductions of MACE and HF hospitalization compared with DPP4i use; SGLT2i addition was not associated with primary MACE prevention.PRIMARY FUNDING SOURCE: VA Clinical Science Research and Development and supported in part by the Centers for Diabetes Translation Research.PMID:37155984 | DOI:10.7326/M22-2751
Source: Annals of Internal Medicine - May 8, 2023 Category: Internal Medicine Authors: Tadarro L Richardson Alese E Halvorson Amber J Hackstadt Adriana M Hung Robert Greevy Carlos G Grijalva Tom A Elasy Christianne L Roumie Source Type: research

Prescription patterns and therapeutic effects of second-line drugs in Japanese patients with type 2 diabetes mellitus: Analysis of claims data for metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycemic agents
CONCLUSIONS: Metformin was suggested to have larger effect to reduce death than sulfonylurea in patients receiving first-line DPP4i. The order of first- and second-line for the DPP4i and metformin combination did not affect the outcomes. Given the nature of the study design, certain limitations, including potential under-adjustment for confounders, should be considered.PMID:37096493 | DOI:10.1080/14656566.2023.2206016
Source: Expert Opinion on Pharmacotherapy - April 25, 2023 Category: Drugs & Pharmacology Authors: Rimei Nishimura Tomomi Takeshima Kosuke Iwasaki Sumiko Aoi Source Type: research

Letter to the Editor regarding “Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes diagnosed after metformin-triggered stroke-like episodes”
We read with interest the article by Murakami et al. about a 40 years-old male with mitochondrial encephalopathy, lactic acidosis, and stroke-like episode (MELAS) syndrome due to the variant m.3243A>G with a heteroplasmy rate of 27%, in whom metformin was suspected to have triggered a stroke-like episode (SLE), the phenotypic hallmark of MELAS.1 Metformin was replaced by sitagliptin and the patient was discharged in a stable condition after three weeks.1 The study is excellent, but has limitations that are objectionable and should be discussed.
Source: Journal of Stroke and Cerebrovascular Diseases - April 20, 2023 Category: Neurology Authors: Josef Finsterer Tags: Letter to the Editor Source Type: research

In reply to the letter to the editor reading: Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes diagnosed after metformin-triggered stroke-like episodes
We are grateful to Josef Finsterer for his comments on our recent report regarding mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) diagnosed after metformin-triggered stroke-like episodes (SLEs).1 In his letter to the editor, several limitations regarding our study were raised.
Source: Journal of Stroke and Cerebrovascular Diseases - April 19, 2023 Category: Neurology Authors: Keishu Murakami, Ken Sakamoto, Hiroshi Ishiguchi, Hidefumi Ito Tags: Letter to the Editor Source Type: research

Top 20 Research Studies of 2022 for Primary Care Physicians
This article summarizes the top 20 research studies of 2022 identified as POEMs (patient-oriented evidence that matters), excluding COVID-19. Statins for primary prevention of cardiovascular disease produce only a small absolute reduction in a person's likelihood of dying (0.6%), having a myocardial infarction (0.7%), or having a stroke (0.3%) over three to six years. Supplemental vitamin D does not reduce the risk of a fragility fracture, even in people with low baseline vitamin D levels or a previous fracture. Selective serotonin reuptake inhibitors are preferred medical therapy for panic disorder, and patients who disco...
Source: Pain Physician - April 13, 2023 Category: Anesthesiology Authors: Roland Grad Mark H Ebell Source Type: research

Metformin adherence and the risk of cardiovascular disease: a population-based cohort study
CONCLUSIONS: This study revealed that metformin adherence in patients with T2DM who required a first-line treatment may reduce the risk of subsequent CVD. Despite the availability of numerous novel antiglycemic agents, metformin adherence by patients who require a combination of antiglycemic agents provides an additional benefit of CVD protection.PMID:37051071 | PMC:PMC10084537 | DOI:10.1177/20406223231163115
Source: Adv Data - April 13, 2023 Category: Epidemiology Authors: Shun-Fan Yu Chien-Tai Hong Wan-Ting Chen Lung Chan Li-Nien Chien Source Type: research

Top 20 Research Studies of 2022 for Primary Care Physicians
This article summarizes the top 20 research studies of 2022 identified as POEMs (patient-oriented evidence that matters), excluding COVID-19. Statins for primary prevention of cardiovascular disease produce only a small absolute reduction in a person's likelihood of dying (0.6%), having a myocardial infarction (0.7%), or having a stroke (0.3%) over three to six years. Supplemental vitamin D does not reduce the risk of a fragility fracture, even in people with low baseline vitamin D levels or a previous fracture. Selective serotonin reuptake inhibitors are preferred medical therapy for panic disorder, and patients who disco...
Source: American Family Physician - April 13, 2023 Category: Primary Care Authors: Roland Grad Mark H Ebell Source Type: research